Charts

News

12 Jul, 2024
Throughout the last three months, 13 analysts have evaluated ACADIA Pharmaceuticals (NASDAQ:ACAD), offering a diverse set of opinions ...
27 Jun, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $197.52 per unit.
25 Jun, 2024
13 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set ...
23 Jun, 2024
21 Jun, 2024
Symbols mentioned in this story: LABU, FDMT, ETNB, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
We recently compiled the list of the 7 Best Halal Stocks To Buy Now (Debt Free). In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against the other debt free halal stocks. Halal Investing: Debt-Free Stocks, Islamic Funds, and Shariah-Compliant Indices Islamic equity investing, also known as […]
18 Jun, 2024
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide).
11 Jun, 2024
Symbols mentioned in this story: LABU, FDMT, ETNB, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
29 May, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. The post 3 Sorry Pharma Stocks to Sell in May While You Still Can appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
24 May, 2024
U.S.drug wholesalerCencora Inc(NYSE:COR), formerlyAmerisourceBergen, is notifying affected individuals about ...
23 May, 2024
Key Insights ACADIA Pharmaceuticals' Annual General Meeting to take place on 29th of May Total pay for CEO Steve Davis...
20 May, 2024
Symbols mentioned in this story: LABU, FDMT, ETNB, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
17 May, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units (“RSUs”) to twenty-two new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
15:12
FinancialContent
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 19th contracts and identified one put and one call contract of particular interest.
15 May, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolia’s Guide to Adventuring, a new, 10-part, documentary video series by award-winning TV producer, AJ Tesler, and his wife, Jenny Tesler, featuring their 13-year-old daughter, Magnolia, who lives with Rett syndrome. The series follows the Teslers as they are joined by other Rett families on adaptive adventures across the U.S., including downhill skiing, ice skating and horseback riding, to foster greater understanding and awareness of Rett syndrome while inspiring those impacted by this condition to be empowered by all the things they can do.
11 May, 2024
It's been a mediocre week for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with the stock dropping 11% to...
10 May, 2024
ACADIA's Revenue Surges with Strong Sales from NUPLAZID and DAYBUE
ACADIA Pharmaceuticals ( NASDAQ:ACAD ) First Quarter 2024 Results Key Financial Results Revenue: US$205.8m (up 74% from...
09 May, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. The post Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript May 8, 2024 ACADIA Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 […]
ACADIA Pharmaceuticals showcases a 74% revenue surge and strategic expansions in its Q1 2024 earnings, underlining strong sales and future market plans.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ACAD stock results show that ACADIA Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. The post ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
08 May, 2024
Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.
07 May, 2024
06 May, 2024
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
04 May, 2024
On May 2, 2024, Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), sold 11,427 shares of the company.
02 May, 2024
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
30 Apr, 2024
ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 25 analysts in the last three months, revealing a diverse range of ...
29 Apr, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year.
28 Apr, 2024
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
26 Apr, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Biotechnology & Genome ETF (PBE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $82.80 per unit.
24 Apr, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
22 Apr, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
17 Apr, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
11 Apr, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. The post 3 Pharma Stocks to Sell in April Before They Crash & Burn appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
10 Apr, 2024
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set ...
02 Apr, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
01 Apr, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.
26 Mar, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Small Cap ETF (AFSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.43 per unit.
22 Mar, 2024
Symbols mentioned in this story: LABU, FDMT, ETNB, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..
19 Mar, 2024
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...
14 Mar, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. The post 3 Pharma Stocks to Sell in March Before They Crash & Burn appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
13 Mar, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.
12 Mar, 2024
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported ...
14:46
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Airline stocks are down on Tuesday as investors deal with several bits of bad news for the industry on Tuesday! The post Why Are Airline Stocks Down Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin. The post Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades ...
Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.
Gainers Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's ...
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Monday,Acadia Pharmaceuticals Inc(NASDAQ:ACAD) released top-line results from the Phase 3 ADVANCE-2 trial evaluating ...
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA ...
11 Mar, 2024
Gainers CareMax (NASDAQ:CMAX) stock increased by 16.9% to $8.0 during Monday's after-market session. The market value of their ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.
08 Mar, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. The post 3 Stock Winners That Are Up 1,000% or More in 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
29 Feb, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time.
26 Feb, 2024
06 Nov, 2023

Related Articles